Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sarepta Must Balance Exondys 51 Confirmatory Trials And Sales

Executive Summary

How will the confirmatory trial necessary to convert accelerated approval to full approval affect sales given the small size of the target population?

You may also be interested in...



PTC Tumbles On Ataluren Failure In Cystic Fibrosis

With a second Phase III failure in nonsense mutation CF, the New Jersey biotech ends development of ataluren for CF, but continues with the drug in three smaller indications.

Sarepta Winning Payer War Over Duchenne Muscular Dystrophy Drug Coverage

Exondys 51 has been met with recommendations for restrictions by many insurers, but after consultations with experts and Sarepta execs coverage is expanding.

Sarepta Eyes Patient Outcomes To Boost Exondys 51's European Review

EMA and payers want to know more about daily life improvements from US FDA-approved Duchenne muscular dystrophy treatment.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC097330

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel